News and Announcements
Viralytics Ltd (ASX:VLA) – CEO Interview
- Published December 14, 2012 10:18AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Viralytics is an Australian Stock Exchange listed company developing a portfolio of Oncolytic viruses that have the potential not only to provide a more effective treatment of a range of cancers, but also a substantial improvement in patients quality of life. Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics’ headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia.
Executive Interviews
Forget the share price. SpaceX just published a map of the next five years.
Most coverage of SpaceX’s result focused on a 9.1% share price fall. That is noise. The signal is in the transcript: compute, power, bandwidth and demand over the next five years.
The prefab company that deliberately leaves part of the house unbuilt
BuiltQuik prefabricates the floor and roof structure and stops there. Co-founder Ryan Mullaney argues the omission is the product. Prefabricated housing usually means a factory. A large central facility, identical modules, limited room to move on design, and a logistics problem getting the finished box to site. BuiltQuik builds the opposite, and the design decision […]
Dogs First to Reduce Risk: QBiotics’ Smarter Path to Oncology Markets
QBiotics took a compound derived from a north Queensland rainforest tree all the way to veterinary registration before pursuing human oncology to de-risk its human cancer programme. Interim CEO Ebru Davidson argues that sequence – now backed by early responses across several human cancers – is the company’s real asset. The story that pulled Wholesale […]
Backed By Leading Investment Groups and Family Offices
